NCT06305559: An ongoing trial by NewAmsterdam Pharma
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06305559 |
|---|---|
| Title | A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 16, 2024 |
| Completion date | Nov. 30, 2027 |
| Required reporting date | Nov. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 27, 2026 |
| Days late | None |